SACUBITRIL; VALSARTAN
| Brand name | ENTRESTO |
|---|---|
| Active ingredient | SACUBITRIL; VALSARTAN |
| Strength | 97MG;103MG |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | July 2015 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11058667 | May 2036 | use U-3170 |
| 11135192 | August 2033 | use U-3084 |
| 9517226 | August 2033 | use U-3084 |
| 9937143 | August 2033 | use U-3084 |
| 8877938*PED | November 2027 | — |
| 8877938 | May 2027 | substance, product |
| 9388134*PED | May 2027 | — |
| 9388134 | November 2026 | use U-1723 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.